Protalix BioTherapeutics
PLX
63 hedge funds and large institutions have $21M invested in Protalix BioTherapeutics in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 19 increasing their positions, 10 reducing their positions, and 5 closing their positions.
405% more call options, than puts
Call options by funds: $838K | Put options by funds: $166K
360% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 5
150% more capital invested
Capital invested by funds: $8.4M → $21M (+$12.6M)
90% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 10
40% more funds holding
Funds holding: 45 → 63 (+18)
4.52% more ownership
Funds ownership: 5.97% → 10.49% (+4.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.05M |
| 2 |
Millennium Management
New York
|
+$1.37M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.23M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$1.15M |
| 5 |
Goldman Sachs
New York
|
+$573K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$341K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$230K |
| 3 |
Morgan Stanley
New York
|
-$207K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$112K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$80.5K |
PLX Hedge Fund Activity: Q1 2025 in Review
63 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2025, worth a combined $21M — up 150% from $8.4M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new PLX positions and 5 closed out — a net gain of 18 holders — while 19 added to existing stakes and 10 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $2.05M. The largest seller was Citadel Advisors, cutting an estimated $341K.
- 63 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2025, up from 45 in Q4 2024.
- Funds reported $21M of Protalix BioTherapeutics stock for Q1 2025, up 150% quarter-over-quarter.
- 23 funds opened new Protalix BioTherapeutics positions in Q1 2025 and 5 closed out, a net change of +18 holders.
- The largest Protalix BioTherapeutics buyer in Q1 2025 was Susquehanna International Group, an estimated $2.05M added.
- The largest Protalix BioTherapeutics seller in Q1 2025 was Citadel Advisors, an estimated $341K sold.
Based on aggregated 13F filings for Q1 2025.